R. Naeije (Brussels, Belgium)
Acetylene single breath estimation of effective pulmonary blood flow in patients with pulmonary arterial hypertension (PAH)
L. S. Mackay, T. Small, A. J. Fisher, J. Lordan, P. A. Corris (Newcastle upon Tyne, United Kingdom)
|  |
ECG and doppler-ECHO studies of hypoxic pulmonary hypertension
B. K. Kojonazarov, B. Z. Imanov, M. M. Mirrakhimov, R. Naeije, M. W. Wilkins, A. A. Aldashev (Bishkek, Kyrgyzstan; Brussels, Belgium; London, United Kingdom)
| |
New and old formula for predicting mean pulmonary artery pressure from doppler – assessed flow parameters in comparison with hemodynamic parameters
L. Lenartowska, J. Lewczuk, P. Piszko, B. Ludwik, M. Stopyra-Poczatek, J. Kowal, D. Drozdz, J. Jagas, M. Mazij (Wroclaw, Poland)
| |
Assessment of pulmonary perfusion by MR in patients suffering from pulmonary arterial hypertension (PAH) in comparison to healthy volunteers
S. Ley, D. Mereles, C. Fink, F. Risse, E. Grünig, H. U. Kauczor (Heidelberg, Munich, Germany)
| |
Value of MR-phase-contrast flow measurements for functional assessment of pulmonary arterial hypertension
S. Ley, D. Mereles, M. Puderbach, E. Grünig, M. Eichinger, J. Zaporozhan, C. Fink, H. U. Kauczor (Heidelberg, Munich, Germany)
| |
Assessment of right ventricular function during exercise by strain or strain rate imaging and ventilatory response in patients with severe pulmonary arterial hypertension
A. Filusch, P. Schoene, B. Meder, G. Ekkehard, K. Hugo, M. Joachim (Heidelberg, Germany)
| |
Comparison of NT-proBNP and BNP in the diagnosis of pulmonary hypertension – influence of renal impairment
H. H. Leuchte, M. El Nounou, R. A. Baumgartner, M. Vogeser, J. Behr (Munich, Muenchen, Germany)
| |
A potential role for sildenafil in the management of pulmonary hypertension associated with parenchymal lung disease
B. P. Madden, T. K. Loke, M. Allenby, A. Sheth (London, United Kingdom)
| |
Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH)
L. S. Mackay, J. O‘Sullivan, G. A. MacGowan, R. Allcock, A. J. Fisher, J. Lordan, P. A. Corris (Newcastle upon Tyne, United Kingdom)
| |
The effect of 12 months Bosentan treatment on congenital heart disease associated pulmonary arterial hypertension
L. S. Mackay, J. O‘Sullivan, G. A. MacGowan, R. Allcock, A. J. Fisher, J. Lordan, P. A. Corris (Newcastle upon Tyne, United Kingdom)
| |
Low dose intravenous iloprost therapy in idiopathic pulmonary arterial hypertension
M. Halank, M. Kolditz, S. Schiemanck, B. Wiedemann, C. Opitz, R. Wensel, G. Hoeffken, R. Ewert (Dresden, Berlin, Regensburg, Greifswald, Germany)
| |
Pulmonary hypertension associated with sarcoidosis and experience of treatment with pentoxifylline (Vasonite)
E. N. Popova, S. B. Bolevich, V. V. Fomin, M. V. Lebedeva, E. A. Kogan (Moscow, Russian Federation)
| |
Bosentan treatment in pulmonary arterial hypertension (PAH) associated with interstitial lung diseases (ILDs)
M. A. Dimadi, F. P. Kokkinis, R. Trigidou, P. Demertzis, E. Dimopoulou, S. Kakouros, K. Malagari, D. Bouros (Athens, Lamia, Alexandroupolis, Greece)
| |
Chronic pulmonary heart finding in autopsy material
V. M. Kosjerina Ostric, Z. M. Kosjerina (Sremska Kamenica, Serbia And Montenegro)
| |
Oral sildenafil is a potent pulmonary vasodilator and improves gas exchange in patients with COPD with pulmonary hypertension
G. Butrous, H. A. Ghofrani, N. Weissmann, R. Schermuly, W. Seeger, F. Grimminger (Sandwich, United Kingdom; Giessen, Germany)
| |
Inhaled endothelin-receptor-blockers in acute pulmonary hypertension in an isolated ventilated and buffer perfused rabbit lung model
H. H. Leuchte, T. Meis, M. El Nounou, J. Behr (Munich, Germany)
| |
Patterns of mean pulmonary artery pressure (mPAP)-flow relation changes following chronic therapy in idiopathic pulmonary arterial hypertension (IPAH)
S. Provencher, P. Herve, O. Sitbon, M. Humbert, G. Simonneau, D. Chemla (Clamart, Le Plessis-Robinson, Le Kremlin-Bicêtre, France)
| |